Long‐Term Proton Pump Inhibitors in Lung Transplant Recipients: Near‐Universal Use Without Clear Impact on Clinical Outcomes Over a 20‐Year Observational Study
Clinical Transplantation · 2026
DOI: 10.1111/ctr.70706 ↗At a glance
Beobachtungsstudie in Clinical Transplantation, 2026. Written by Chen Yang Kevin Zhang and 9 co-authors. Institution: Toronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, Canada. Major MEDLINE topics: Proton Pump Inhibitors, Lung Transplantation, Gastroesophageal Reflux, Graft Rejection. 17 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: University Health Network Foundation.
Abstract (original language)
Background
Gastroesophageal reflux disease (GERD) is a known risk factor for chronic lung allograft dysfunction (CLAD), the main barrier to long‐term survival in lung transplant recipients (LTR). While proton pump inhibitors (PPI) are effective for symptomatic treatment of GERD, data are sparse on the prevalence of long‐term PPI use and association with clinical outcomes.
Methods
Single‐center retrospective cohort of adult first‐time LTR between 1999 to 2018 who were alive and CLAD‐free at 1‐year post‐transplant. PPI exposure was defined as ≥8 continuous weeks in the first year, started within 6 months post‐transplant.
Results
1308 LTR were included, with 1170 (89.4%) exposed to PPI. PPI use increased over time and remained above 90% from 2007 onwards. In multivariable analyses, LTR on PPI had similar time to CLAD and time to death/retransplant compared to those not on PPI. Similarly, no differences in outcomes were observed between LTR on once‐daily and twice‐daily dosing, or after accounting for the number of reflux episodes on 24 h pH‐impedance monitoring. Positive bronchoalveolar lavage cultures and acute rejection over the first‐year post‐transplant was also comparable.
Conclusions
Long‐term use of PPI became near‐universal without observable effect on clinical outcomes. While further research is needed, these findings question the routine use of PPI in LTR.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Toronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, Canada.
- Biostatistics Research Unit, University Health Network, Toronto, Canada.
Funding
- University Health Network Foundation
Cite
APA
Zhang, C. Y. K., Ramendra, R., Aversa, M., Ghany, R., Tikkanen, J., Huszti, E., Yeung, J., Keshavjee, S., Singer, L. G., & Martinu, T. (2026). Long‐Term Proton Pump Inhibitors in Lung Transplant Recipients: Near‐Universal Use Without Clear Impact on Clinical Outcomes Over a 20‐Year Observational Study. Clinical Transplantation. https://doi.org/10.1111/ctr.70706
Vancouver
Zhang CYK, Ramendra R, Aversa M, Ghany R, Tikkanen J, Huszti E, et al. Long‐Term Proton Pump Inhibitors in Lung Transplant Recipients: Near‐Universal Use Without Clear Impact on Clinical Outcomes Over a 20‐Year Observational Study. Clinical Transplantation. 2026. doi:10.1111/ctr.70706
BibTeX
@article{Zhang2026,
author = {Zhang, Chen Yang Kevin and Ramendra, Rayoun and Aversa, Meghan and Ghany, Rasheed and Tikkanen, Jussi and Huszti, Ella and Yeung, Jonathan and Keshavjee, Shaf and Singer, Lianne G and Martinu, Tereza},
title = {Long‐Term Proton Pump Inhibitors in Lung Transplant Recipients: Near‐Universal Use Without Clear Impact on Clinical Outcomes Over a 20‐Year Observational Study},
journal = {Clinical Transplantation},
year = {2026},
doi = {10.1111/ctr.70706}
}
EUVIMED